Another big pharma ventures into TCM

GlaxoSmithKline (GSK) recently announced that it is forming a new research team in China focusing on traditional Chinese medicine (TCM) related development.

GSK is determined to take a different approach than the typical westernization of TCM, e.g. trying to screen out the active ingredients and tu...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

New insights about human immune response to COVID-19 have implications for vaccine design against new variants

News Commentary | May 07, 2021

Multiple new and emerging COVID‑19 variants with higher transmission rates have thrown into question the continued efficacy of existing vaccines across these newer strains. Previous research has focused on the receptor‑binding domain (RBD) given its importance in attaching to and infecting human ... To read more, click here.

Google-backed Calico and AbbVie announce second extension of a long-standing partnership to tackle aging-related diseases

News Commentary | July 30, 2021

Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription

Regulus Therapeutics

Company Profile | December 01, 2021

Regulus Therapeutics was created as a joint venture between Alnylam Pharmaceuticals, an RNAi therapeutics company, and Isis Pharmaceuticals (now known as Ionis Pharmaceuticals), a company focused on anti‑sense technologies and therapeutics, in 2007 Regulus Therapeutics is focused on the ... Not part of subscription